Pharmacogenetic analyses in people with dementia in Northeast Germany.

IF 4.4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2026-07-14 eCollection Date: 2026-07-01 DOI:10.1002/dad2.70423

Marleen Julia Meyer-Tönnies, Leefke Schwarz, Diana Wucherer, Wolfgang Hoffmann, Jochen René Thyrian, Mladen Vassilev Tzvetkov

{"title":"Pharmacogenetic analyses in people with dementia in Northeast Germany.","authors":"Marleen Julia Meyer-Tönnies, Leefke Schwarz, Diana Wucherer, Wolfgang Hoffmann, Jochen René Thyrian, Mladen Vassilev Tzvetkov","doi":"10.1002/dad2.70423","DOIUrl":null,"url":null,"abstract":"Introduction: Pharmacogenetics-guided prescribing may reduce adverse drug reactions by 30%. European and American expert groups (Dutch Pharmacogenetics Working Group and Clinical Implementation Consortium) issue genotype-based dosage recommendations, but pharmacogenetic testing is still not routinely used. Here, we assess the potential of pharmacogenetic testing to optimize pharmacotherapy in people with dementia (PwD).Methods: We genotyped variants in CYP2D6 , CYP2C9, CYP2C19, CYP3A4, CYP3A5, and SLCO1B1 genes and related them to individual medication data in 115 PwD from an epidemiological cohort from Northeast Germany.Results: The vast majority of PwD (93%) carried at least one actionable variant. Fourteen (12%) had at least one strongly actionable variant. Four of them (4%) took the drug affected and carried the strongly actionable genetic variant.Discussion: Pharmacogenetic testing may contribute to improved pharmacotherapy in PwD. The potential improvements were mainly for medications commonly taken by elderly, but also for medications used to treat or associated with progression of dementia.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"18 3","pages":"e70423"},"PeriodicalIF":4.4000,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13368705/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70423","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Pharmacogenetics-guided prescribing may reduce adverse drug reactions by 30%. European and American expert groups (Dutch Pharmacogenetics Working Group and Clinical Implementation Consortium) issue genotype-based dosage recommendations, but pharmacogenetic testing is still not routinely used. Here, we assess the potential of pharmacogenetic testing to optimize pharmacotherapy in people with dementia (PwD).

Methods: We genotyped variants in CYP2D6 , CYP2C9, CYP2C19, CYP3A4, CYP3A5, and SLCO1B1 genes and related them to individual medication data in 115 PwD from an epidemiological cohort from Northeast Germany.

Results: The vast majority of PwD (93%) carried at least one actionable variant. Fourteen (12%) had at least one strongly actionable variant. Four of them (4%) took the drug affected and carried the strongly actionable genetic variant.

Discussion: Pharmacogenetic testing may contribute to improved pharmacotherapy in PwD. The potential improvements were mainly for medications commonly taken by elderly, but also for medications used to treat or associated with progression of dementia.

查看原文本刊更多论文

德国东北部痴呆症患者的药物遗传学分析。

药物遗传学指导处方可减少30%的药物不良反应。欧洲和美国专家组（荷兰药物遗传学工作组和临床实施联盟）发布了基于基因型的剂量建议，但药物遗传学检测仍未常规使用。在这里，我们评估药物遗传学测试在优化痴呆症（PwD）患者药物治疗中的潜力。方法：我们对来自德国东北部流行病学队列的115名PwD患者的CYP2D6、CYP2C9、CYP2C19、CYP3A4、CYP3A5和SLCO1B1基因变异进行基因分型，并将其与个体用药数据进行关联。结果：绝大多数PwD（93%）携带至少一种可操作的变异。14例（12%）至少有一种强烈可操作的变异。其中4人（4%）服用了受影响的药物并携带了强烈可操作的遗传变异。讨论：药物遗传学检测可能有助于改善PwD的药物治疗。潜在的改善主要是针对老年人常用的药物，但也针对用于治疗或与痴呆症进展相关的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.